Regarding CKD models, an increase in mortality has been observed in preclinical trials using a high-affinity blockade of FGF23 [62]; however, an increase in survival has been observed in end-stage CKD patients using calcimimetics as the inhibition of PTH production results in a modest reduction in FGF23 levels [168]. This evidence concerns the gene FGF23 and chronic kidney disease.